These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38202281)

  • 1. WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think.
    Weissmiller AM; Fesik SW; Tansey WP
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting WDR5: A WINning Anti-Cancer Strategy?
    Aho ER; Weissmiller AM; Fesik SW; Tansey WP
    Epigenet Insights; 2019; 12():2516865719865282. PubMed ID: 31360909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.
    Lu K; Tao H; Si X; Chen Q
    Front Oncol; 2018; 8():502. PubMed ID: 30488017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
    Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
    Gao W; Jia Z; Tian Y; Yang P; Sun H; Wang C; Ding Y; Zhang M; Zhang Y; Yang D; Tian Z; Zhou J; Ruan Z; Wu Y; Ni B
    Hepatology; 2020 May; 71(5):1678-1695. PubMed ID: 31544250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders.
    Gurung R; Om D; Pun R; Hyun S; Shin D
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GRWD1-WDR5-MLL2 Epigenetic Complex Mediates H3K4me3 Mark and Is Essential for Kaposi's Sarcoma-Associated Herpesvirus-Induced Cellular Transformation.
    Wei S; Lu S; Liang L; Wang X; Li W; Li T; Chen L; Ju E; Zhang X; Lai Z; Huang Y; Lu X; Gao SJ
    mBio; 2021 Dec; 12(6):e0343121. PubMed ID: 34933446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders.
    Dölle A; Adhikari B; Krämer A; Weckesser J; Berner N; Berger LM; Diebold M; Szewczyk MM; Barsyte-Lovejoy D; Arrowsmith CH; Gebel J; Löhr F; Dötsch V; Eilers M; Heinzlmeir S; Kuster B; Sotriffer C; Wolf E; Knapp S
    J Med Chem; 2021 Aug; 64(15):10682-10710. PubMed ID: 33980013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
    Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
    Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets.
    Liu L; Guo X; Wang Y; Li G; Yu Y; Song Y; Zeng C; Ding Z; Qiu Y; Yan F; Zhang YX; Zhao C; Zhang Y; Dou Y; Atadja P; Li E; Wang H
    Biochim Biophys Acta Mol Basis Dis; 2023 Feb; 1869(2):166600. PubMed ID: 36402263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
    Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
    J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WIN site inhibition disrupts a subset of WDR5 function.
    Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
    Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors.
    Teuscher KB; Mills JJ; Tian J; Han C; Meyers KM; Sai J; South TM; Crow MM; Van Meveren M; Sensintaffar JL; Zhao B; Amporndanai K; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
    J Med Chem; 2023 Dec; 66(24):16783-16806. PubMed ID: 38085679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.
    Ding J; Li G; Liu H; Liu L; Lin Y; Gao J; Zhou G; Shen L; Zhao M; Yu Y; Guo W; Hommel U; Ottl J; Blank J; Aubin N; Wei Y; He H; Sage DR; Atadja PW; Li E; Jain RK; Tallarico JA; Canham SM; Chiang YL; Wang H
    ACS Chem Biol; 2023 Jan; 18(1):34-40. PubMed ID: 36594833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MYC-WDR5 Nexus and Cancer.
    Thomas LR; Foshage AM; Weissmiller AM; Tansey WP
    Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
    Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
    J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high WDR5 expression on the hepatocellular carcinoma prognosis.
    Cui Z; Li H; Liang F; Mu C; Mu Y; Zhang X; Liu J
    Oncol Lett; 2018 May; 15(5):7864-7870. PubMed ID: 29731905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
    Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
    J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.
    Yu X; Li D; Kottur J; Kim HS; Herring LE; Yu Y; Xie L; Hu X; Chen X; Cai L; Liu J; Aggarwal AK; Wang GG; Jin J
    J Med Chem; 2023 Dec; 66(23):16168-16186. PubMed ID: 38019706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of WD repeat domain 5 associates with aggressive clinicopathological features and unfavorable prognosis in head neck squamous cell carcinoma.
    Wu Y; Diao P; Li Z; Zhang W; Wang D; Wang Y; Cheng J
    J Oral Pathol Med; 2018 May; 47(5):502-510. PubMed ID: 29569374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.